Relapsed/Refractory LBCL
Advertisement
Liso-cel Versus Standard of Care as Second-Line Therapy for Relapsed/Refractory LBCL
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 3, 2023
The chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) significantly improved event-free ...
Read More
Advertisement
Advertisement
Advertisement
Latest News

EMBER-3 Trial: Imlunestrant Improves PROs in ER+/HER2– Breast Cancer

May 31, 2025

Oral Paclitaxel Non-Inferior to IV Paclitaxel in HER2-Negative mBC

May 31, 2025

DESTINY-Breast06: T-DXd Outperforms Chemo in HER2-Low/Ultralow HR+ mBC Across Mutations

May 31, 2025

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Editorial Policy

    Advertising

    Connect

    Contact Us

    eNewsletters

    Contribute

    Career Center

    Our Network

    MashupMD

    Blood Cancers Today

    Cancer Nursing Today

    GU Oncology Now

    Urban Health Today

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |